Treatment of Ocular Myasthenia Gravis

Update Item Information
Identifier 20190318_nanos_hottopic1_02
Title Treatment of Ocular Myasthenia Gravis
Creator Michael Lee, MD
Subject Ocular Myasthenia; Treatment; Therapy; Pyridostigmine; Corticosteroids; Thymectomy; Azathioprine; Mycophenolate Mofetil
Description Myasthenia gravis is caused by pathogenic autoantibodies to the postsynaptic neuromuscular junction. Clinically, this may affect any of the skeletal muscles causing variable weakness, which worsens with continued muscle activity. Ocular myasthenia gravis (OMG) may affect the levator palpebrae superioris, extraocular muscles, and orbicularis oculi causing ptosis and diplopia. Meanwhile, generalized myasthenia gravis (GMG) refers to involvement of the non-ocular skeletal muscles. This talk will focus on treatment strategies for OMG. Discussion of the diagnosis of OMG and the treatment of GMG is beyond the scope.
Date 2019-03
Language eng
Format video/mp4
Source 2019 North American Neuro-Ophthalmology Society Annual Meeting
Relation is Part of NANOS Annual Meeting 2019: Hot Topics: How Do I Treat?
Collection Neuro-ophthalmology Virtual Education Library: NOVEL
Publisher Spencer S. Eccles Health Sciences Library, University of Utah
Holding Institution North American Neuro-Ophthalmology Association. NANOS Executive Office 5841 Cedar Lake Road, Suite 204, Minneapolis, MN 55416
Rights Management Copyright 2019. For further information regarding the rights to this collection, please visit:
ARK ark:/87278/s6478s6d
Context URL The NANOS Annual Meeting Neuro-Ophthalmology Collection:
Contributor Primary Michael Lee, MD
Setname ehsl_novel_nam
ID 1426195
Reference URL